---
title: "Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances"
description: "Alkermes plc anticipates record proprietary product sales exceeding $1 billion for 2025, driven by strong Q2 performance and advancements in its orexin pipeline. CEO Richard F. Pops highlighted sustai"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250649067.md"
published_at: "2025-07-29T19:01:27.000Z"
---

# Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances

> Alkermes plc anticipates record proprietary product sales exceeding $1 billion for 2025, driven by strong Q2 performance and advancements in its orexin pipeline. CEO Richard F. Pops highlighted sustained profitability, no debt, and over $1 billion in cash. Q2 revenues reached $390.7 million, with proprietary product net sales of $307.2 million, reflecting 14% year-over-year growth. The company is on track to meet or exceed its financial guidance, with expectations for continued growth in proprietary product sales. Analysts expressed cautious optimism regarding safety and regulatory pathways for alixorexton, while management remained confident in its data and product efficacy.

Earnings Call Insights: Alkermes plc (ALKS) Q2 2025 Management View Richard F. Pops, CEO, described the quarter as "very successful" and highlighted "strong commercial and financial performance" with Alkermes "on track to deliver on our key objectives across the business" for 2025. He stated, "With sustained profitability now, no debt and more than...

### Related Stocks

- [ALKS.US - Alkermes](https://longbridge.com/en/quote/ALKS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Irish Court Approves Avadel Pharmaceuticals Acquisition by Alkermes | The Irish High Court has approved the acquisition of Avadel Pharmaceuticals plc by Alkermes plc. The court sanctioned th | [Link](https://longbridge.com/en/news/275510100.md) |
| Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares | Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, has reported the disposal of common shares of the | [Link](https://longbridge.com/en/news/271991860.md) |
| Alkermes Touts $10B Sleep Market as ALKS 2680 Heads to Phase 3, Avidel Deal Nears Close | Alkermes (NASDAQ: ALKS) presented at the J.P. Morgan Healthcare Conference, highlighting its strong growth foundation as | [Link](https://longbridge.com/en/news/272469823.md) |
| Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares | Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reported the disposal of common shares of the com | [Link](https://longbridge.com/en/news/271362738.md) |
| FDA Grants Breakthrough Therapy Designation to Alkermes' Alixorexton for Narcolepsy Type 1 | Alkermes plc has received Breakthrough Therapy designation from the FDA for its investigational drug alixorexton, aimed  | [Link](https://longbridge.com/en/news/271647276.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
